Slide 1: Orion Result Presentation 1-12/2020
Orion Result Presentation 1−12/2020
Slide 2: Disclaimer
Disclaimer This presentation contains forward-looking statements which involve risks and uncertainty factors. These statements are not based on historical facts but relate to the Company’s future activities and performance. They include statements about future strategies and anticipated benefits of
Slide 3: Highlights in January-December 2020
Highlights in January-December 2020
Slide 4: Strong performance amid the challenges posed by the COVID-19 pandemic
Strong performance amid the challenges posed by the COVID-19 pandemic COVID-19 • Orion was able to secure the continuity of production. • No disruptions in the availability of products or raw materials. • Securing the health and safety of employees and patients in on-going clinical trials was a prio
Slide 5: Key figures 1−12/2020
Key figures 1−12/2020 Net sales Operating profit Operating profit Cash flow per share margin before financial items 1,078 280 26% 1.85 MEUR (1,051) MEUR (253) (24%) EUR (1.68) +3% +11% +10% Result presentation 1-12/2020 © Orion Corporation 9 February 2021 5
Slide 6: Development of net sales in 1-12/2020 vs. 1-12/2019
Development of net sales in 1-12/2020 vs. 1-12/2019 11 -7 1,078 31 1,051 14 3 -20 -16 11 * Nubeqa® product sales & royalty ** Proprietary Products and Specialty Products *** Animal Health, Fermion and Contract Manufacturing **** Without Nubeqa® royalties Result presentation 1-12/2020 © Orion Corpora
Slide 7: Development of operating profit in 1-12/2020 vs. 1-12/2019
Development of operating profit in 1-12/2020 vs. 1-12/2019 9 -14 25 6 280 -2 3 253 * Product & service sales without sales margin and product mix change and exchange rate effect *** Exchange rate effect on gross margin ** Product sales margin and product mix change but without exchange rate effect R
Slide 8: Geographical breakdown and development of net sales
Geographical breakdown and development of net sales 1-12/2020 MEUR 1-12/2020 1-12/2019 13% 400 +10% 29% +2% 8% 350 368 300 334 316 309 250 +0% 200 +5% 150 177 177 -20% 34% 16% 100 135 128 103 50 83 Finland Scandinavia 0 Other Europe North America RoW RoW = Rest of the World Result presentation 1-12/
Slide 9: All units showed growth
All units showed growth 1−12/2020 1−12/2019 1-12/2020 MEUR +3% +3% 7% 498 486 8% 500 420 406 400 39% 300 +4% +6% 200 46% 89 86 75 71 100 Proprietary Products 0 Specialty Products Specialty Proprietary Animal Fermion and Animal Health Products Products Health Contract Manufacturing Fermion & CM Resul
Slide 10: TOP 10 products in 1-12/2020
TOP 10 products in 1-12/2020 EUR million vs. 1-12/2019 1. Easyhaler® product portfolio 115 +10% 2. Stalevo®, Comtess®, Comtan® 99 +1% 3. Simdax® 62 -8% 4. dexdor® 55 -3% 5. Dexdomitor®, Domitor®, Domosedan®, Antisedan® 35 -4% 6. Burana® 23 -6% 7. Divina® series 21 +8% 8. Remsima®, Ritemvia®, Amgevit
Slide 11: Proprietary Products
Proprietary Products 6 RION ing well-being Buildi
Slide 12: Nubeqa® and Easyhaler® product portfolio growth drivers
Nubeqa® and Easyhaler® product portfolio growth drivers Proprietary Products MEUR +10% sales split 1-12/2020 140 +1% 115 17% 120 24% 104 99 98 -6% 100 -8% 4% -3% 80 68 73 77 62 60 55 57 +609% 40 15% 17 20 2 27% 0 13% Easyhaler® Parkinson's Simdax® Dexdor® Nubeqa® Others portfolio franchise Parkinson
Slide 13: Easyhaler® product portfolio sales +10%
Easyhaler® product portfolio sales +10% 1-12/2020 Budesonide-formoterol Easyhaler® MEUR 72 (62) +15% 40 1-12/2020 Other Easyhaler® products MEUR 43 (42) +2% 30 Sales, MEUR 20 10 0 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 2016 2017 2018 2019 2020 Other Budesonide-formoterol Easyhal
Slide 14: Parkinson's franchise sales at similar level to 2019
Parkinson’s franchise sales at similar level to 2019 – strong variation within the year 1-12/2020 Own sales MEUR 48 (46) +6% 50 45 1-12/2020 Deliveries to partners MEUR 50 (52) -3% 40 35 Sales, MEUR 30 25 20 15 10 5 0 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 2016 2017 2018 2019 20
Slide 15: Dexdor® and Simdax® - impact of generic competition starting to show
Dexdor® and Simdax® - impact of generic competition starting to show 1-12/2020 Dexdor® MEUR 55 (57) -3% 1-12/2020 Simdax® MEUR 62 (68) -8% 20 20 15 15 10 10 5 5 0 0 2016 2017 2018 2019 2020 2016 2017 2018 2019 2020 Result presentation 1-12/2020 © Orion Corporation 9 February 2021 15
Slide 16: Specialty Products
Specialty Products
Slide 17: Strong generic prescription sales in Scandinavia mitigated the decline due to biosimilars
Strong generic prescription sales in Scandinavia mitigated the decline due to biosimilars MEUR +3% Sales split 1−12/2020 300 280 272 14% 250 200 14% 150 -12% +3% +23% 89 100 78 70 68 71 56% 57 50 16% 0 Finland Scandinavia Eastern RoW Europe & Finland Russia Scandinavia Eastern Europe & Russia 1-12/2
Slide 18: Strong year for Gx prescription drugs even without COVID-19 impact
Strong year for Gx prescription drugs even without COVID-19 impact – biosimilars declined as anticipated MEUR +8% Sales split 1−12/2020 400 358 3% 350 331 300 25% 250 +4% 200 150 122 118 -53% 100 38 50 18 72% 0 Generic Self Care Biosimilars Generic drugs prescription products drugs Self-care product
Slide 19: Specialty Products' sales change vs. 2019
Specialty Products’ sales change vs. 2019 35 40% 30% 25 20% 10% 15 0% EUR million -10% 5 -20% -5 -30% -40% -15 -50% -60% -25 -70% Q1 Q2 Q3 Q4 FY20 Q1 Q2 Q3 Q4 FY20 Gx prescription drugs Self Care Biosimilars Gx prescription drugs Self Care Biosimilars Result presentation 1-12/2020 © Orion Corporatio
Slide 20: In Finland, market for reference priced prescription drugs levelled off
In Finland, market for reference priced prescription drugs levelled off after demand spike in March The market for reference priced prescription drugs in Finland* The sales of Orion's reference (1−12/2020) priced prescription drugs in Finland MEUR 449 (452) MEUR 110 (108) Market development Orion’s
Slide 21: Orion is strong in home market Finland
Orion is strong in home market Finland Human pharma market in Finland 1−12/2020 Reference Self-care Medicinal and non-medicinal products priced products in hospital and pharmacy channels: EUR 2,903 million prescription Orion market share in MEUR drugs pharmacy 350 316 Orion market share in 300 pharm
Slide 22: Research and development
Research and development
Slide 23: Key clinical development pipeline
Key clinical development pipeline Phase completed Phase ongoing Project/compound Indication Phase I Phase II Phase III Registration ARASENS / darolutamide 1 Prostate cancer (mHSPC) Phase I Phase II Phase III ARANOTE / darolutamide 1 Prostate cancer (mHSPC) Phase I Phase II Phase III ODM-208 Prostate
Slide 24: Key business targets in 2021
Key business targets in 2021 TARGET STATUS Supporting sales growth and co-promotion in Europe with Bayer Positive outcome from Phase III ARASENS trial Taking phase III ARANOTE trial forward together with Bayer Sales growth ODM-208 Taking the development program forward according to plan Finland Main
Slide 25: Orion's sustainability and COVID-19
Orion’s sustainability and COVID-19 ORION’S SUSTAINABILITY AGENDA Ensuring patient safety and reliable supply of Responsibility for employees, the environment medications and the ethics and transparency of operations • Ensuring reliable supply of medications is the most • Taking care of the health a
Slide 26: Orion's Sustainability Agenda and indicators 2020
Orion’s Sustainability Agenda and indicators 2020 Patient safety and ensuring Responsibility for reliable supply of medications the environment Business ethics and Responsibility for Orionees transparency Customer Greenhouse gas Energy savings Injury rate Code of Conduct complaints GxP* audits emiss
Slide 27: Outlook
Outlook GRION Building well-being
Slide 28: Outlook for 2021
Outlook for 2021 Net sales Orion estimates that in 2021 net sales will be slightly lower than in 2020 (net sales in 2020 were EUR 1,078 million). Operating profit Operating profit is estimated to be lower or clearly lower than in 2020 (in 2020 operating profit was EUR 280 million). Result presentati
Slide 29: Key assumptions behind the outlook
Key assumptions behind the outlook Net sales Operating profit + Nubeqa® + Nubeqa® + Other growing products + No more depreciation expenses from Parkinson’s franchise - Milestones - Milestones - dexdor® - dexdor® - Simdax® - Simdax® - Animal Health - Normalisation of cost level (without Parkinson’s d
Slide 30: Royalties and milestones
Royalties and milestones Includes significant part of EUR 50 million 80 darolutamide collaboration signing fee from Bayer Includes EUR 28 million milestones from Bayer for the first commercial sales of darolutamide in EU and JPN 70 Includes EUR 45 million milestone from Bayer for the 60 first commer
Slide 31: 2025 Growth target: New Proprietary Products and R&D pipeline as growth drivers
2025 Growth target: New Proprietary Products and R&D pipeline as growth drivers – all units target for organic growth OPPORTUNITIES THREATS/CHALLENGES Darolutamide* ARASENS & ARANOTE Generic competition Easyhaler® tiotropium* Animal Health R&D* Failures in R&D programmes In-licensing and product acq
Slide 32: Upcoming events
Upcoming events Annual General Meeting 25/3/2021 Interim Report 1-3/2021 27/4/2021 Capital Markets Day 2021 26/5/2021 Half-Year Financial Report 19/7/2021 Interim Report 1-9/2021 20/10/2021
Slide 33: Building well-being
Building well-being GRIoN Building well-being